Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
49.64 SEK | +12.82% | +21.07% | +89.47% |
31/05 | Hansa Biopharma Finalizes Patient Randomization for Use of Imlifidase inKidney Transplantation Trial | MT |
31/05 | Hansa Biopharma Completes Randomization in Pivotal Phase 3 Us Confides Trial | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+89.47% | 298M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- HNSA Stock
- News Hansa Biopharma AB
- Transcript : Hansa Biopharma AB Presents at 39th Annual JPMorgan Virtual Healthcare Conference, Jan-14-2021 04